reports
Lexicon to Present Data on Effect of Kidney Function on the Long-term ...
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function...
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, ...
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders – Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clini...
PBF Energy Inc: 1 director
Two Directors at PBF Energy Inc sold/sold after exercising options 1,158,100 shares at between 43.351USD and 44.795USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results ...
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- (Na...
Ring Energy Releases Fourth Quarter and Full Year 2025 Results, Year-E...
Ring Energy Releases Fourth Quarter and Full Year 2025 Results, Year-End 2025 Proved Reserves, and Provides 2026 Guidance THE WOODLANDS, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today reported operational and financial results for the fourth quarter and full year 2025, year-end 2025 proved reserves and provided 2026 operational and financial guidance. Fourth Quarter 2025 Highlights Sold 13,124 barrels of oil per day (“Bo/d”), near the mid-point of guidance and 20,508 barrels of oil equivalent per day (“Boe/d”) which was a...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events...
Cellectar Biosciences Reports Financial Results for Year Ended 2025 an...
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NAS...
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investo...
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recording and re...
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
- Jonathan Moreland
VNO VORNADO REALTY TRUST
TYL TYLER TECHNOLOGIES INC.
TBI TRUEBLUE INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PODD INSULET CORPORATION
NEU NEWMARKET CORPORATION
MYGN MYRIAD GENETICS INC.
MSCI MSCI INC. CLASS A
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HMN HORACE MANN EDUCATORS CORPORATION
HCI HCI GROUP INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
CEVA CEVA INC.
CAR AVIS BUDGET GROUP INC.
OFIX ORTHOFIX INTERNATIONAL N.V.
WY WEYERHAEUSER COMPANY
TZOO TRAVELZOO
FIVN FIVE9 INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
SXC SUNCOKE ENERGY INC.
WINA WINMARK CORP.
ITIC INVESTORS TITLE CO.
GGT THE GABELLI MULTIMEDIA TRUST
CNDT CONDUENT INC.
HLNE HAMILTON LANE INCORPORATED CLASS A
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
BOTJ BANK OF THE JAMES FINANCIAL GROUP INC.
UBER UBER TECHNOLOGIES INC.
AVTR AVANTOR
VERX INC.
BIGC VERTEX
NBR INC.
SLQT BIGCOMMERCE HOLDINGS
DLHC NABORS INDUSTRIES LTD.
ABCL SELECTQUOTE
CVRX INC.
ELF DALEIGH HOLDINGS CORP
FLYW ABCELLERA BIOLOGICS
BLCO CVRX
FSCO INC.
CADL E.L.F. BEAUTY
CVI INC.
TLSI FLYWIRE CORP
ASST BAUSCH + LOMB CORP
EKSO FS CREDIT OPPORTUNITIES CORP.
LNZA CANDEL THERAPEUTICS
INC.
CVR ENERGY
INC.
TRISALUS LIFE SCIENCES INC
ASSET ENTITIES INC.
EKSO BIONICS HOLDINGS INC.
LANZATECH GLOBAL INC
Moody's Ratings affirms Crown Castle's Baa3 ratings, changes outlook t...
Moody's Ratings (Moody's) today affirmed Crown Castle Inc.'s ("Crown Castle" or the "the REIT") Baa3 senior unsecured debt ratings. In the same rating action, we affirmed the REIT's Prime-3 commercial paper (CP) rating, (P)Baa3 senior unsecured shelf rating and (P)Ba1 subordinate shelf and preferred...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Result...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website ...
StoneX Digital Launches Digital Asset Lending Capability
StoneX Digital Launches Digital Asset Lending Capability NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- StoneX Group Inc. (“StoneX”; NASDAQ: SNEX) today announced that StoneX Digital, a division of StoneX, has launched a digital asset lending capability, expanding the firm’s existing brokerage and financing services for institutional clients. StoneX Digital connects institutional clients to digital asset markets through spot execution, listed products, such as exchange-traded funds and futures, and financing solutions within a single institutional framework. The introduction of this lending...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
POOL POOL CORPORATION
NEU NEWMARKET CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HTGC HERCULES CAPITAL INC.
AMH AMERICAN HOMES 4 RENT CLASS A
GGT THE GABELLI MULTIMEDIA TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SONO SONOS
VERX VERTEX
WRB INC.
W.R. BERKLEY CORPORATION
Crown Castle Declares Quarterly Common Stock Dividend
Crown Castle Declares Quarterly Common Stock Dividend HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") announced today that its Board of Directors has declared a quarterly cash dividend of $1.0625 per common share. The quarterly dividend is payable on March 31, 2026, to common stockholders of record at the close of business on March 13, 2026. Future dividends are subject to the approval of Crown Castle's Board of Directors. ABOUT CROWN CASTLE Crown Castle owns, operates and leases approximately 40,000 cell towers and approximately 90,000 route mi...
Cellectar Biosciences to Report Full Year Financial Results and Host a...
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 ...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
AXTI AXT INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
OSTK OVERSTOCK.COM INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZS ZSCALER INC.
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
BEAM INC.
LRMR BEAM THERAPEUTICS
VRDN LARIMAR THERAPEUTICS INC
PLTK VIRIDIAN THERAPEUTICS INC
DAWN PLAYTIKA HOLDING
XMTR DAY ONE BIOPHARMACEUTICALS INC
STX XOMETRY
GLUE INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
S MONTE ROSA THERAPEUTICS INC
GETY GLOBALFOUNDRIES INC
SENTINELONE INC
GETTY IMAGES HOLDINGS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.